Question 7: Newer macrolides: inappropriate for first-line therapy of respiratory tract infections?

20 June, 2018

Question 7
It has been reported that even newer macrolides are no longer an appropriate choice for first-line therapy of RTIs, and may be of questionable value as second-line therapy in areas of high DRSP. Would you agree with this statement, and if so, why?